158 related articles for article (PubMed ID: 30064682)
41. Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration.
Comuth WJ; Henriksen LØ; van de Kerkhof D; Husted SE; Kristensen SD; de Maat MPM; Münster AB
Thromb Res; 2018 Apr; 164():32-39. PubMed ID: 29475179
[TBL] [Abstract][Full Text] [Related]
42. The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma.
Zhang C; Zhang P; Li H; Han L; Zhang L; Zhang L; Yang X
Thromb Res; 2018 May; 165():38-43. PubMed ID: 29558660
[TBL] [Abstract][Full Text] [Related]
43. Inhibitory effects of dabigatran etexilate, a direct thrombin inhibitor, on osteoclasts and osteoblasts.
Rocha AL; Bighetti-Trevisan RL; Duffles LF; de Arruda JAA; Taira TM; Assis BRD; Macari S; Diniz IMA; Beloti MM; Rosa AL; Fukada SY; Goulart GAC; Ribeiro DD; Abreu LG; Silva TA
Thromb Res; 2020 Feb; 186():45-53. PubMed ID: 31883999
[TBL] [Abstract][Full Text] [Related]
44. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR;
Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635
[TBL] [Abstract][Full Text] [Related]
45. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
46. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
[TBL] [Abstract][Full Text] [Related]
47. Venous malformations with severe localized intravascular coagulopathy treated with microwave ablation.
Tai MZ; Wang YP; Chen T; Li KL; Xu ZG; Ge CX; Qin ZP; Zheng JW
Vascular; 2022 Aug; 30(4):779-786. PubMed ID: 34144653
[TBL] [Abstract][Full Text] [Related]
48. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Aug; 98(2):333-8. PubMed ID: 17721615
[TBL] [Abstract][Full Text] [Related]
49. Hemopericardium in a patient treated with dabigatran etexilate.
Barton CA; McMillian WD; Raza SS; Keller RE
Pharmacotherapy; 2012 May; 32(5):e103-7. PubMed ID: 22488474
[TBL] [Abstract][Full Text] [Related]
50. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.
Postma MJ; Kappelhoff BS; van Hulst M; Brouwers JR
J Med Econ; 2012; 15(5):878-86. PubMed ID: 22563715
[TBL] [Abstract][Full Text] [Related]
51. Thrombotic Complications in Venous Malformations: Are There Differences Between Facial and Other Localizations?
Soudet S; Dakpe S; Le Gloan S; Carmi E; Arnault JP; Testelin S; Plancq MC; Devauchelle B; Sevestre MA
Clin Appl Thromb Hemost; 2020; 26():1076029620968143. PubMed ID: 33085511
[TBL] [Abstract][Full Text] [Related]
52. Prediction of venous malformations with localized intravascular coagulopathy with diffusion-weighted magnetic resonance imaging.
Razek AA; Ashmalla GA
Phlebology; 2019 Apr; 34(3):156-161. PubMed ID: 29720044
[TBL] [Abstract][Full Text] [Related]
53. [Overt disseminated intravascular coagulation complicating a venous malformation].
Zenati N; Seinturier C; Blaise S
Rev Med Interne; 2021 Feb; 42(2):131-133. PubMed ID: 33168353
[TBL] [Abstract][Full Text] [Related]
54. Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers.
Arellano-Rodrigo E; Lopez-Vilchez I; Galan AM; Molina P; Reverter JC; Carné X; Villalta J; Tassies D; Lozano M; Díaz-Ricart M; Escolar G
Transfus Med Rev; 2015 Oct; 29(4):242-9. PubMed ID: 26364029
[TBL] [Abstract][Full Text] [Related]
55. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
56. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
57. [Monitoring of Oral Thrombin Inhibitor].
Matsuno K; Usami T; Hatuse M; Shimizu C
Rinsho Byori; 2014 Oct; 62(10):958-64. PubMed ID: 27526541
[TBL] [Abstract][Full Text] [Related]
58. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
Gulseth MP; Wittkowsky AK; Fanikos J; Spinler SA; Dager WE; Nutescu EA
Pharmacotherapy; 2011 Dec; 31(12):1232-49. PubMed ID: 22122184
[TBL] [Abstract][Full Text] [Related]
59. Chronic localized intravascular coagulation complicating multifocal venous malformations.
Martin LK; Russell S; Wargon O
Australas J Dermatol; 2009 Nov; 50(4):276-80. PubMed ID: 19916972
[TBL] [Abstract][Full Text] [Related]
60. Laboratory measurement of the direct oral anticoagulants.
Dale BJ; Chan NC; Eikelboom JW
Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
